Page 2 - Eris Lifesciences

Boehringer Ingelheim obtains ad-interim injunctions on 4 Indian pharma cos

The firms had launched generic versions of Boehringer's patent-protected drug Linagliptin, which is marketed under the brand name Trajenta

Eris acquires Oaknet Healthcare for Rs 650 cr for dermatology foray

With a revenue base of Rs 195 crore in FY22, Oaknet brings a portfolio of leading brands in dermatology and women's health to the Eris stable.

Eris sees a sweet spot as it forays into insulin market, eyes 10% share

Eris Lifesciences (Eris) is foraying into an oligopolistic insulin market with its own insulin brand this month

Eris Lifesciences Q3 PAT up 12% to Rs 90 cr, revenue rises 7%

The company launched four new products in the first nine months of FY22, more on the anvil

Eris Lifesciences soars 10% on JV with MJ Biopharm to enter insulin segment

The purpose of entering into the agreement is expansion of product portfolio to offer biotherapeutic options to the patients in cardio-metabolic segment, Eris said in statement

Eris Lifesciences forms JV with MJ Biopharm to enter insulin segment

Eris MJ Biopharm, the 70:30 joint venture (with Eris holding a 70 per cent stake), would primarily engage in marketing and distribution of human and analogue insulin

Eris Lifesciences Q4 PAT up 21% YoY on strong show by superspecialty biz

Consolidated total income up 13%; robust anti-diabetic sales, new product pipeline, expanded coverage of cardiologists support better numbers

Eris Lifesciences Q3 net up 42% to Rs 90 cr, total income rises by 14%

Overall, the company saw decent growth in its product segments, led by cardio metabolic and vitamin-mineral-nutrients

Eris Lifesciences' Q2 net rises 16%, consolidated income grows 14.5%

Eris continued to demonstrate strong focus on its top 15 power brands

Eris Lifesciences consolidated Q4 PBT up 5.9% at Rs 62 cr, income rises 9%

Full-year pre-tax profit up 4.46% at Rs 331.52 cr

Eris Lifesciences soars 7%, hits five-month high in a weak market

In October, some large domestic mutual funds took an aggressive position in the stock, monthly disclosures show

Eris Lifesciences surges 7%, hits 5-month high in a weak market

In the past one month, the stock has outperformed the market by surging 17 per cent, as compared to a marginal 0.35 per cent rise in the S&P BSE Sensex.

Eris Lifesciences climbs 3% after it acquires trademark Zomelis for $13 mn

Used in the treatment of type 2 diabetes, Zomelis comes under a new class of anti-diabetic drugs known as DPP 4 inhibitors.

Eris Lifesciences gains 6% as 3% equity changes hands via block deals

Around 3.82 million equity shares, representing 2.78 per cent of total equity, of Eris Lifesciences changed hands on the BSE, the exchange data shows.

Eris Lifesciences hits record low as stock turns ex-date for share buyback

On July 3, the company's board approved buyback of shares worth up to Rs 100 crore. The buyback is for 1.74 million shares at Rs 575 per share.

From Linedex to UTH: Eris' acquired portfolio moving in a slow lane

After growing organically for almost a decade, Eris had made four acquisitions of distressed businesses in a couple of years

Eris Lifesciences trades higher for fifth straight trading day

Stock of the pharmaceutical company outperformed the market by gaining 12% in past five trading days, as compared to 1.3% decline in the S&P BSE Sensex.

Eris Life extends rally post acquisition of Strides' India branded business

The stock rallied 11% to Rs 721, extending its 11% gain in past six trading sessions.

Eris Lifesciences eyes high-margin segments

In 2016, Eris acquired 75.48% in Kinedex, for an aggregate consideration of Rs 77.18 crore

Eris Lifesciences acquires UTH Healthcare for Rs 12.85 crore

This is the company's first acquisition after being listed on the exchanges earlier this year